Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 146 Breast Neoplasms 112 Prostatic Neoplasms 59 Multiple Myeloma 55 Neoplasms 54 Lung Neoplasms 49 Neoplasm Metastasis 42 Colorectal Neoplasms 34 Ovarian Neoplasms 33 Parkinson Disease 4, Autosomal Dominant Lewy Body 31 Leukemia, Lymphocytic, Chronic, B-Cell 31 Recurrence 26 Leukemia, Myeloid, Acute 26 Carcinoma, Renal Cell 25 Urinary Bladder Neoplasms 24 Triple Negative Breast Neoplasms 21 Small Cell Lung Carcinoma 21 Myasthenia Gravis 21 Endometrial Neoplasms 21 Carcinoma, Hepatocellular 21 Squamous Cell Carcinoma of Head and Neck 20 Lymphoma, Large B-Cell, Diffuse 20 Melanoma 18 Lymphoma, Follicular 18 Nasopharyngeal Carcinoma 17 Fallopian Tube Neoplasms 16 Pancreatic Neoplasms 15 Non-Muscle Invasive Bladder Neoplasms 15 Brain Neoplasms 15 Stomach Neoplasms 14

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × mCRPC × 90 days × Clear all

NCT03395197 2026-04-22

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡